Page 5 - Alkermes News Today

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ALKS stock, giving a Buy rating yesterday. Chris Shibutani has giv...

Alkermes plc (NASDAQ:ALKS – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The […]

Moody Aldrich Partners LLC lifted its stake in Alkermes plc (NASDAQ:ALKS – Free Report) by 31.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 52,570 shares of the company’s stock after buying an additional 12,496 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Alkermes […]

Moody Aldrich Partners LLC boosted its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 31.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,570 shares of the company’s stock after purchasing an additional 12,496 shares during […]

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.

On Tuesday, Alkermes plc ALKS revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b,…

Stocks that are trading heavily or have substantial price changes on Tuesday: BlackBerry, Alkermes rise; Neogen, Tilray Brands fall.

BioPharma

China Universal Asset Management Co. Ltd. boosted its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 352.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,306 shares of the company’s stock after buying an additional 15,035 shares during the quarter. China […]

Marketresearch.biz reports that the Increasing incidence of schizophrenia in developed economies, growing awareness among individuals about treatments for schizophrenia, and increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving the growth of the global schizo...